Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

NCT05743244 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

NIH

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Abrocitinib 200 MG Oral Tablet
DRUG: Ritlecitinib
DRUG: Placebo

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborators

[object Object]